The Effect of Tamoxifen of the Estrogen Receptor cDNA-Iipofected MDA-MB-231 Human Breast Cancer Cells.
10.4048/jkbcs.1998.1.2.192
- Author:
Young Jin SUH
1
;
Sang Seol JUNG
;
Woo Chan PARK
;
Seung Hye CHOI
;
Se Chung OH
;
Woun Il CHO
;
Jae Hak LEE
;
In Chul KIM
Author Information
1. Department of Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Breast cancer;
Estrogen receptor;
Gene therapy;
Tamoxifen;
Lipofection
- MeSH:
Breast Neoplasms*;
Breast*;
Cell Count;
Cell Line;
DNA, Complementary;
Estradiol;
Estrogen Receptor Modulators;
Estrogens*;
Genetic Therapy;
Humans*;
Receptors, Progesterone;
Tamoxifen*;
Transfection
- From:Journal of Korean Breast Cancer Society
1998;1(2):192-202
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: The loss of estrogen and progesterone receptors appears to be associated with a progression to less-differentiated and hormone-independent tumors. The gain of hormone independency over time even in estrogen receptor-positive tumors has become another obstacle to endocrine therapy for breast cancer. We tried to regain the hormone dependency in estrogen receptor-negative breast cancer cells by lipofecting estrogen receptor cDNA. MATERIALS AND METHODS: The mutant human estrogen receptor cDNA (pSG5-HE0) was lipofected into estrogen receptor-negative human breast cancer cell line MDA-MB-231, in an attempt to restore their sensitivity to antiestrogen. Then the effects if 17 beta -estradiol and tamoxifen were studied by counting viable cell numbers after treating the lipofected cell line with either one or together. RESULTS: The cell growth was most profoundly inhibited in 4 days after lipofection with mutant human estrogen receptor cDNA, which was overcome after that days. Tamoxifen, as an antiestrogen, showed a growth inhibitory effect slightly strong over combined conditions of tamoxifen and 17 beta estradiol compared to estrogen-treated group and to control. CONCLUSIONS: The temporary induction of estrogen receptor by lipofection with pSG5-HE0 on estrogen receptor-negative human breast cancer cell line MDA-MB-231 showed negative growth control on these cells by tamoxifen, indicating that liposome-mediated estrogen receptor transfection may be used as a novel therapeutic strategy for hormone independent human breast cancers in the near future.
